{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009245","form_type":"8-K","ticker":null,"cik":"0000876378","company_name":"ASENSUS SURGICAL, INC.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.108497+00:00","generated_at":"2026-06-04T08:53:40.224451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Asensus Surgical reports Q4 revenue $5.4M; going concern; cash only through early June 2024","bullets":["Q4 2023 revenue $5.4M vs $2.5M YoY; net loss $17.2M ($0.07/share) vs $17.9M ($0.08).","Full year 2023 revenue $8.6M; 8 Senhance programs initiated; 3,550+ procedures (+13% YoY).","Cash and equivalents $21.1M at Dec 31, 2023; expects cash to sustain operations only until early June 2024.","Company will file 10-K with going concern qualification from independent auditor.","LUNA system development on track: design freeze expected H2 2024; Flex agreement for manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009245","json":"https://secwatch.observer/filing/0001437749-24-009245.json","markdown":"https://secwatch.observer/filing/0001437749-24-009245.md","text":"https://secwatch.observer/filing/0001437749-24-009245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876378/000143774924009245/0001437749-24-009245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876378/000143774924009245/asxc20240321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:53:40.224451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf44baa2db318320cb013c9c12ba07df9504c2e6","claim":"ASENSUS SURGICAL, INC. reported the fourth quarter and year ended December 31, 2023 results: revenue $8.6 million.","evidence_excerpt":"growth of over 13% compared to 2022 ● In 2023, 8 Senhance Surgical Programs were initiated, which is in line with guidance of 8-10 systems ● Full year 2023 revenue of $8.6 million ● The Company had cash, cash equivalents and short-term investments, excluding restricted cash, of approximately $21.1 million at December 31, 2023 Fourth Quarter Highlights ●","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876378/000143774924009245/0001437749-24-009245-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$8.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}